AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Singular Health (ASX:SHG) Advances US Market Reach with Strategic PNS Deal and Capital Raise
June 19, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,Singular Health (SHG) inks a $2 million deal to expand its 3D medical imaging platform in the US,Secures $8 million strategic placement to fund expansion and innovation,Partnership with US-based PNS aims to tackle systemic healthcare ineff...
Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update
June 19, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,Formycon AG shareholders approve all agenda items at its annual general meeting,Supervisory Board expanded with re-election of Klaus Röhrig and appointment of Dr. Graham Dixon,Management outlines strategic vision for biosimilar market deve...
Orthocell's Remplir Delivers Breakthrough in Nerve Repair, Strengthening Global Ambitions
June 19, 2025 02:32 PM AEST| By Team Kalkine MediaHighlights,Remplir outperforms traditional nerve repair methods,Orthocell’s US market entry gains momentum,Global expansion continues with strong regulatory support,Orthocell Ltd (ASX:OCC) has reported highly encouraging interim results from a pivota...
Neuren Pharmaceuticals (ASX:NEU) Shows Strong Metrics Despite Market Pullback | ASX 300
June 19, 2025 02:28 PM AEST| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals continues to display robust return on equity within the healthcare sector,Earnings growth remains high compared to broader industry benchmarks,Retained profits signal reinvestment into operations for long-term develo...
Race Oncology Hits Key Milestone in RC220 Clinical Trial
June 19, 2025 02:06 PM AEST| By Team Kalkine MediaHighlights,First patient dosed with RC220 + doxorubicin in Phase 1 trial,Trial targets reduced cardiotoxicity in advanced solid tumours,Global sites and strong preclinical backing boost momentum,Race Oncology (ASX:RAC) has reached a major clinical de...
ASX200 Biotech Breakthrough: Amplia (ASX:ATX) Achieves Rare Success in Pancreatic Cancer Trial
June 19, 2025 01:16 PM AEST| By Team Kalkine MediaHighlights,Amplia,Therapeutics reports second complete response in pancreatic cancer trial,Narmafotinib,shows rare efficacy in advanced stage cases,Encouraging progress for ASX-listed biotech in high-mortality cancer treatment,Amplia Therapeutics (AS...
Why ResMed (ASX:RMD) Is Gaining Attention Among ASX200 Healthcare Stocks
June 19, 2025 11:48 AM AEST| By Team Kalkine MediaHighlights,ResMed (RMD) gains over 5% in 2025 YTD.,Strong global footprint and dual growth in medical tech and SaaS.,Healthcare's consistent revenue and ESG relevance,supports,interest.,ResMed (ASX:RMD), a global medical technology company, has seen...
Cochlear (ASX:COH) Faces Service Division Drag Amid Lowered Guidance
June 18, 2025 10:44 PM AEST| By Team Kalkine MediaHighlights,Cochlear Ltd (ASX:COH) operates within the ASX 200 healthcare sector,The company revised its earnings guidance due to weaker service division performance,Launch of Kanso 3 Sound Processor aimed at long-term recovery,Cochlear Ltd (ASX:COH)...
Healius (ASX:HLS) Sees IVD Growth Momentum in Australia Healthcare Landscape
June 18, 2025 06:13 PM AEST| By Team Kalkine MediaHighlights,Healius Limited (ASX:HLS) operates in the in vitro diagnostics space within the healthcare sector,The stock is part of the ASX 200 and contributes to Australia's growing diagnostic capabilities,Demand for pathology and diagnostic services...
ASX200 Biotech Player Imugene (ASX:IMU) Strengthens US IP Position with Key Patent Grant
June 18, 2025 02:43 PM AEST| By Team Kalkine MediaHighlights,Imugene receives key US patent for innovative cancer therapy.,CF33-CD19 aims to expand CAR T cell treatment to solid tumours.,Supports Imugene’s strategy in global immuno-oncology.,Imugene (ASX:IMU), a clinical-stage immuno-oncology compan...
Biotech Firm Tetratherix (TTX) Sets ASX Listing Date Amid Expansion Drive
June 18, 2025 02:40 PM AEST| By Team Kalkine MediaHighlights,Tetratherix Ltd is preparing to debut on the,ASX 200,under the ticker TTX with a listing date set for the end of June.,The biotech company is commercialising its injectable biostealth fluid matrix designed for regenerative medicine.,Funds...
Mayne Pharma Shareholders Endorse $672M Cosette Deal as ASX200 Court Clash Looms
June 18, 2025 01:12 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma investors overwhelmingly support $672M Cosette acquisition,Legal battle over deal termination to unfold in September,Mayne Pharma’s stock trades below the agreed acquisition value,Mayne Pharma Group Ltd (ASX:MYX), a pharmaceut...
Neuren Pharmaceuticals Sees ASX200 Momentum as Market Eyes EMA Approval
June 18, 2025 01:09 PM AEST| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals shares gain amid strategic momentum,Royalty-rich partnership with Acadia drives earnings leverage,EMA approval eyed, boosting potential future revenue,Neuren Pharmaceuticals (ASX:NEU), a biopharmaceutical company kno...
Cochlear’s New Tech Sparks Market Enthusiasm as ASX200 Giant Targets Global Growth
June 18, 2025 10:46 AM AEST| By Team Kalkine MediaHighlights,Cochlear expects growth with new product release,Nucleus,Nexa,may strengthen global market share,Services revenue projected to rise 40% in three years,Cochlear Limited (ASX:COH), a prominent player in the global hearing solutions industry...
Pro Medicus (ASX:PME) Strengthens Position in Radiology Software Sector | ASX 200
June 17, 2025 07:51 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus Ltd (ASX:PME) delivers healthcare imaging software across global markets,The company forms part of the ASX 200, contributing to the broader australian share market,Strong focus on innovation with a history of software developme...
4DMedical (ASX:4DX) Expands Stanford Partnership, Strengthening ASX300 Medical Imaging Innovation
June 17, 2025 03:24 PM AEST| By Team Kalkine MediaHighlights,4DMedical (4DX) renews and expands contract with Stanford’s 3DQ Lab,Agreement includes cutting-edge lung imaging tech ahead of FDA clearance,Enhanced U.S. research foothold supports momentum within ASX300 stocks,4DMedical Limited (ASX:4DX)...
Recce Pharmaceuticals (ASX:RCE) Strengthens Clinical Pipeline via Avenue Capital Deal | ASX 200
June 17, 2025 03:01 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals secures a significant non-dilutive facility from Avenue Capital to enhance its late-stage clinical trials.,Funding supports registrational Phase 3 trials of R327G in Australia and Indonesia.,Pro-forma cash position en...
CSL (ASX:CSL) Advances in ASX300 with FDA Nod for Innovative HAE Therapy
June 17, 2025 02:30 PM AEST| By Team Kalkine MediaHighlights,CSL (CSL) gains FDA approval for new HAE treatment.,ANDEMBRY becomes first XIIa-targeting therapy for HAE prevention.,Immediate US launch expected through specialty pharmacy network.,CSL Limited (ASX:CSL), one of the prominent,ASX300 stock...
Clarity Pharmaceuticals (ASX:CU6) Secures Manufacturing Deal to Accelerate Commercial Launch
June 17, 2025 12:01 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals signs major U.S. manufacturing deal,Production capacity set to reach 400,000 doses annually,Deal paves way for commercial launch post FDA nod,Clarity Pharmaceuticals (ASX:CU6), a clinical-stage radiopharmaceutical c...
Biotech Player CSL Gains FDA Nod for Rare Genetic Disorder Therapy
June 17, 2025 10:50 AM AEST| By Team Kalkine MediaHighlights,CSL (CSL) secures FDA approval for new HAE treatment,Andembry,to launch in the US for patients aged 12 and above,CSL strengthens its global leadership in rare disease therapies,Global biotechnology leader CSL (ASX:CSL), part of the ASX200...
Advertise your brand on Kalkine Media